Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Baylor Genetics | RCV000000546 | SCV001520379 | pathogenic | Methylmalonic aciduria and homocystinuria type cblF | 2020-06-26 | criteria provided, single submitter | clinical testing | This variant was determined to be pathogenic according to ACMG Guidelines, 2015 [PMID:25741868]. This variant has been previously reported as disease-causing [PMID 19136951] |
Genetic Services Laboratory, |
RCV001818113 | SCV002064501 | pathogenic | not provided | 2017-09-19 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001818113 | SCV004170885 | likely pathogenic | not provided | 2023-04-20 | criteria provided, single submitter | clinical testing | Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; This variant is associated with the following publications: (PMID: 31589614, Braz2022[thesis], 19136951, 34958133) |
Labcorp Genetics |
RCV000000546 | SCV004293771 | pathogenic | Methylmalonic aciduria and homocystinuria type cblF | 2024-03-20 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Thr172Argfs*10) in the LMBRD1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in LMBRD1 are known to be pathogenic (PMID: 19136951, 21303734). This variant is present in population databases (rs779151199, gnomAD 0.02%). This premature translational stop signal has been observed in individual(s) with LMBRD1-related conditions (PMID: 34958133). ClinVar contains an entry for this variant (Variation ID: 517). For these reasons, this variant has been classified as Pathogenic. |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV004782001 | SCV005395077 | pathogenic | Cobalamin C disease | 2024-09-10 | criteria provided, single submitter | clinical testing | Variant summary: LMBRD1 c.515_516delCA (p.Thr172ArgfsX10) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. The variant allele was found at a frequency of 2.8e-05 in 251120 control chromosomes. c.515_516delCA has been reported in the literature the homozygous state in at least 1 individual affected with clinical features of LMBRD1-related conditions (example, Braz_2022). The following publication has been ascertained in the context of this evaluation (PMID: 34958133). ClinVar contains an entry for this variant (Variation ID: 517). Based on the evidence outlined above, the variant was classified as pathogenic. |
Fulgent Genetics, |
RCV000000546 | SCV005672783 | pathogenic | Methylmalonic aciduria and homocystinuria type cblF | 2024-06-19 | criteria provided, single submitter | clinical testing | |
OMIM | RCV000000546 | SCV000020695 | pathogenic | Methylmalonic aciduria and homocystinuria type cblF | 2009-02-01 | no assertion criteria provided | literature only |